Drugs / E39
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02019524 | Sep 2013 → Dec 2016 | breast cancer, ovarian cancer | COL George Peoples, MD, FACS | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E39 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02019524 ↗ |
| Known as | E39 peptide (EIWTHSYKV, Folate Binding Protein, 191-199) | “E39 peptide (EIWTHSYKV, Folate Binding Protein, 191-199)” NCT02019524 ↗ |
| Modality | Vaccine | “E39 and J65 are cytotoxic T-lymphocyte-eliciting peptide vaccines” NCT02019524 ↗ |